↓ Skip to main content

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

Overview of attention for article published in Arthritis Research & Therapy, December 2019
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
19 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis
Published in
Arthritis Research & Therapy, December 2019
DOI 10.1186/s13075-019-2022-8
Pubmed ID
Authors

Jeffrey R. Curtis, Fenglong Xie, Jonathan Kay, Joel D Kallich

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 19 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 26%
Other 3 16%
Researcher 3 16%
Professor 1 5%
Student > Doctoral Student 1 5%
Other 2 11%
Unknown 4 21%
Readers by discipline Count As %
Medicine and Dentistry 5 26%
Pharmacology, Toxicology and Pharmaceutical Science 3 16%
Agricultural and Biological Sciences 2 11%
Nursing and Health Professions 1 5%
Business, Management and Accounting 1 5%
Other 4 21%
Unknown 3 16%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 January 2020.
All research outputs
#14,608,799
of 25,387,668 outputs
Outputs from Arthritis Research & Therapy
#2,125
of 3,383 outputs
Outputs of similar age
#230,447
of 474,537 outputs
Outputs of similar age from Arthritis Research & Therapy
#42
of 77 outputs
Altmetric has tracked 25,387,668 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,383 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 474,537 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.